Beyond Cancer announces publication of pre-clinical data on tumor ablation tech

Beyond Cancer announced the publication of pre-clinical data demonstrating that its proprietary tumor ablation technology utilizing UNO results in a potent innate and adaptive immune response that prevents metastases and resulted in a statistically significant survival benefit. The data were published in an article entitled, "Gaseous Nitric Oxide Tumor Ablation Induces an Anti-Tumor Abscopal Effect," in the peer-reviewed journal Cancer Cell International. The manuscript published in CCI describes several studies of in-vitro and in-situ tumor ablation utilizing a single intratumoral treatment of UNO with secondary anti-tumor effects. In one study, CT26 tumor-bearing mice were treated with a single 5-minute administration of 50,000 ppm gaseous nitric oxide or 20,000 ppm gNO versus naive control. Two weeks post gas treatment, the tumors were resected and a week later a secondary tumor was induced in the contralateral flank. As shown in the figure below at day 55, all of the mice treated with 50,000 ppm gNO rejected the secondary CT26 cell inoculation versus none of the mice in the naive group. In addition, 73% of the mice treated with 20,000 ppm gNO rejected the secondary inoculation, also a significantly better result than naive control. By Day 75, the conclusion of the study, 89% of the mice treated with 50,000 ppm gNO and 64% of the mice treated with 20,000 ppm gNO rejected a secondary inoculation, compared to none of the mice in the naive group. The Kaplan-Meier analysis in the figure above shows statistical significance for survival in UNO treated CT26 tumor-bearing mice versus control. There was also a separation between the 50,000 ppm arm and the 20,000 ppm arm implying a potential dose response.